Read the latest updates in Kidney Cancer presented at ASCO-GU and learn more about KCCure’s presentation on Kidney Cancer Patient Centered Research.
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder).
For the second year in a row, KCCure participated in this important kidney cancer conference. But 2018 was a special year of “firsts” for our organization:
Presenting the patient view to doctors who treat kidney cancer.
- Based on survey results, our abstract was accepted and our poster was included at the conference. We had the opportunity to share with doctors what matters most to patients when they’re considering therapy options.
Representing patients on the NCI Renal Task Force.
- Last December, KCCure president Dena Battle was elected to a three-year term on this important task force that focuses on clinical trials in kidney cancer and participated in her first in-person meeting during ASCO-GU.
Showing off the new KCCure Patient Advisory Board.
- In addition to sharing the news about the PAB with physicians and industry representatives – three members personally attended the conference: Bryan Lewis, George Hall, and Bill Paseman.
In addition to the exciting advances in patient centered participation, we were also watching closely and are excited to report on new announcements related to kidney cancer research.
New Research for Kidney Cancer:
The two most talked about presentations were:
- Data from a trial combining atezolizumab (Tecentriq) and bevacizumab (Avastin) (IMmotion151). This combination outperformed sunitinib (Sutent) for patients who were PD-L1 positive. It remains to be seen how this data will change the recommended treatments for RCC – but we will continue to watch closely.
- Phase 2 trial data on combining axitinib (Inlyta) with pembrolizumab (Keytruda). This combination of immunotherapy and targeted therapy continues to show impressive results with overall response rates exceeding 70 percent in patients. We still need to wait for Phase 3 trial results with this combination, but the phase 2 data looking very promising.
We look forward to continuing to represent the patient voice at conferences like ASCO-GU and to continue updating the patient community on the latest announcements in research!